CompletedPhase 2NCT03694262
The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)
Studying Carcinosarcoma of the corpus uteri
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Medical College of Wisconsin
- Principal Investigator
- William Bradley, MDMedical College of Wisconsin
- Intervention
- Rucaparib(drug)
- Enrollment
- 30 enrolled
- Eligibility
- 18 years · FEMALE
- Timeline
- 2019 – 2026
Study locations (3)
- Mount Sinai, New York, New York, United States
- St. Luke's Hospital and Health Network, Bethlehem, Pennsylvania, United States
- Froedtert Lutheran Memorial Hospital, Milwaukee, Wisconsin, United States
Collaborators
Genentech, Inc. · Clovis Oncology, Inc.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03694262 on ClinicalTrials.govOther trials for Carcinosarcoma of the corpus uteri
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07029399A Study With NKT5097 for Adults With Advanced/Metastatic Solid TumorsNiKang Therapeutics, Inc.
- RECRUITINGPHASE2NCT05619913EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine CarcinosarcomaAustralia New Zealand Gynaecological Oncology Group
- ACTIVE NOT RECRUITINGPHASE2NCT05147558A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT03686124ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid TumorsImmatics US, Inc.